| Nutraceuticals: opening the debate for a regulatory framework |
61 |
| The pharmacokinetics and the pharmacodynamics of cannabinoids |
43 |
| Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D |
39 |
| A systematic review of cannabidiol dosing in clinical populations |
29 |
| The relationship between frailty and polypharmacy in older people: A systematic review |
29 |
| Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents |
24 |
| Long-term adverse effects of paracetamol - a review |
22 |
| Pharmacology of bisphosphonates |
21 |
| Prevalence and incidence of prescription opioid analgesic use in Australia |
20 |
| Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations |
17 |
| Trends in analgesic consumption in France over the last 10years and comparison of patterns across Europe |
16 |
| A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG RO7034067), a SMN2 splicing modifier |
16 |
| Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects |
14 |
| The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth |
14 |
| Hospital readmissions, mortality and potentially inappropriate prescribing: a retrospective study of older adults discharged from hospital |
13 |
| Mechanisms that drive bone pain across the lifespan |
13 |
| A review of the growing risk of vitamin D toxicity from inappropriate practice |
13 |
| Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials |
13 |
| Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK |
12 |
| MEDI a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study |
12 |
| Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland |
12 |
| Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients |
12 |
| Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France |
12 |
| Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease |
12 |
| Critical evaluation of causality assessment of herb-drug interactions in patients |
12 |
| Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients |
12 |
| Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects |
11 |
| Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device |
11 |
| Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data |
11 |
| Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure |
11 |
| Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects |
11 |
| Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study |
11 |
| Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects |
11 |
| Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia |
11 |
| Anti-IL-7 receptor alpha monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study |
11 |
| Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial |
11 |
| Drug-drug interaction potential in men treated with enzalutamide: Mind the gap |
11 |
| Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy |
11 |
| A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients |
11 |
| Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study |
10 |
| Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting |
10 |
| Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions |
10 |
| The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis |
10 |
| Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome |
10 |
| Large differences in neonatal drug use between NICUs are common practice: time for consensus? |
10 |
| Side effects of drugs for osteoporosis and metastatic bone disease |
10 |
| Dasatinib-induced pulmonary arterial hypertension |
10 |
| An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting |
9 |
| Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis |
9 |
| Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease |
9 |
